Canada Markets close in 2 hrs 42 mins

Merck & Co., Inc. (MRK)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
81.88+0.34 (+0.42%)
As of 01:18PM EST. Market open.
Sign in to post a message.
  • a
    alshammari
    http://the-alphatrader.com/ is truly one of the best stock advice newsletters out there! Their daily emails give me all the information I need to trade more wisely each day. I rely heavily on their watchlists and recommend all traders should do the same!
  • D
    Dennis
    Keytruda with FDA approval for tx of 16 different CA’s, expanding its use among oncology providers. Bless those (and their families) facing this diagnosis
  • F
    FEDERICO
    I believe the trend up will continue going into the report on Thursday, Feb. 3. which I also believe they will post a huge quarter, beat on revenue and beat on earnings, huge year overall and they will give a great outlook for another big year ahead for revenues and earnings, and continue increase in dividend pay.

    Heading to and ALL TIME HIGH of $100 per share and the Q4 and year end report will be the tailwind needed for MRK to become a great boring holding for at least the next 5 years that will provide great capital gains while getting paid along the way.

    Onward and Upward

    Blessings
  • R
    Real Immuno Investor 10
    $SLS conversation
    Not if but when SLS shares are $100+ - Now is A Great Time to Invest in $SLS
    REGAL phase 3 compares Gps vs Existing SOC, Dr. Levy, Baylor Med Research Director for Hematology explained known SOC survival rates are 5/6 months. He also explained, (still online) all previous Gps trial data confirmed a strong and powerful Immune Response, that correlated to extended survival. Patients have more WT1 Cancer killing tcells and Live longer. Simple and straightforward. Existing treatments (defined on the NCT site for REGAL) have known outcomes. Gps has extended median overall survival in every single trial, in AML, Myeloma, Mesothelioma, Ovarian cancer. In the Moffit center phase 2 GPs extended Os to 21 months vs 5 wBAT.

    The IDMC is now reviewing and analyzing the Registrational phase 3 for Efficacy. In this open Label, single blind trial they are able to discontinue for Efficacy per the statistical analysis plan (SAP) if they see a clear signal, in this 24 month old trial.

    The AML Remission maintenance trial ($200M annual market) is the First of several cancers Gps treats, over 20.

    The SAP Registration includes a 10 month median OS FDA approval trigger for GPS vaccinated patients.

    SLS has partnerships with with $MRK $BMY, Gps is currently in combination w Keytruda and Opdivo - Results are now due for a Sponsor Investigated (MSKM) Mesothelioma Trial and a Pivotal Phase 2 Ovarian cancer trial.

    Let me know if you have any questions. I am a shareholder and have posted much dd.
  • R
    Real Immuno Investor 10
    $SLS conversation
    Not if, only when SLS shares trade for $100+ Jazz paid $1.5B for a lessor AML drug. $XBI beatdown is A Great Time to Invest. Dr. Levy, Baylor Med Research Director for Hematology explained AML SOC survival rates are 5/6 months. He also explained, (still online) all previous Gps trial data confirmed a strong and powerful Immune Response, that correlated to extended survival. Patients have more WT1 Cancer killing t cells and Live longer. Simple and straightforward. Existing treatments (defined on the NCT site for REGAL) have known outcomes. Gps has extended median overall survival in every single trial, in AML, Myeloma, Mesothelioma, Ovarian cancer. In the Moffit center phase 2 GPs extended Os to 21 months vs 5 wBAT.

    The IDMC is now reviewing and analyzing the Registrational phase 3 for Efficacy. In this open Label, single blind trial they are able to discontinue for Efficacy per the statistical analysis plan (SAP) if they see a clear signal, in this 24 month old trial.

    The AML Remission maintenance trial ($200M annual market) is the First of several cancers Gps treats, over 20.

    The SAP Registration includes a 10 month median OS FDA approval trigger for GPS vaccinated patients.

    SLS has partnerships with with $MRK $BMY, Gps is currently in combination w Keytruda and Opdivo - Results are now due for a Sponsor Investigated (MSKM) Mesothelioma Trial and a Pivotal Phase 2 Ovarian cancer trial.

    Let me know if you have any questions. I am a shareholder and have posted much dd.
  • R
    Real Immuno Investor 10
    $XBI conversation
    Not if but when SLS shares are $100+ - Now is A Great Time to Invest in $SLS
    REGAL phase 3 compares Gps vs Existing SOC, Dr. Levy, Baylor Med Research Director for Hematology explained known SOC survival rates are 5/6 months. He also explained, (still online) all previous Gps trial data confirmed a strong and powerful Immune Response, that correlated to extended survival. Patients have more WT1 Cancer killing tcells and Live longer. Simple and straightforward. Existing treatments (defined on the NCT site for REGAL) have known outcomes. Gps has extended median overall survival in every single trial, in AML, Myeloma, Mesothelioma, Ovarian cancer. In the Moffit center phase 2 GPs extended Os to 21 months vs 5 wBAT.

    The IDMC is now reviewing and analyzing the Registrational phase 3 for Efficacy. In this open Label, single blind trial they are able to discontinue for Efficacy per the statistical analysis plan (SAP) if they see a clear signal, in this 24 month old trial.

    The AML Remission maintenance trial ($200M annual market) is the First of several cancers Gps treats, over 20.

    The SAP Registration includes a 10 month median OS FDA approval trigger for GPS vaccinated patients.

    SLS has partnerships with with $MRK $BMY, Gps is currently in combination w Keytruda and Opdivo - Results are now due for a Sponsor Investigated (MSKM) Mesothelioma Trial and a Pivotal Phase 2 Ovarian cancer trial.

    Let me know if you have any questions. I am a shareholder and have posted much dd.
  • B
    Bernard Baruch
    $GNPX CEO says they are now looking forward to REQORSA cancer interim data NEXT in interview with Proactive (link below). Genprex has two sets of interim data for REQORSA with Keytruda combo and the Tagrisso combo, now both in progress. $MRK Keytruda brings in $20billion in revenues a year and $AZN Tagrisso brings in $4billion a year.
    Genprex is undervalued today and will be even more after interim data release.
    https://www.genprex.com/videos/
  • M
    ManBySea
    Went from all cash today to back in 25%…
    Equal $ amts in $SENS $PAYX $FB $AAPL $DKS $PG $PFE $MRK
  • F
    FEDERICO
    All gaps have been fully close.

    Now is time to build a solid uptrend this year and print and ALL TIME HIGH, going towards that $100 per share mark.

    Great place to park some money waiting to increase capital and getting paid as we wait. And then using that money to buy into some of the oversold and undervalue small cap Bio/Pharma stocks.

    Onward and Upward

    Blessings
  • R
    Real Immuno Investor 10
    $SLS conversation
    Published 2021 Nov 9 Dr. Peoples, who conducted the $GLSI trial that added a billion in instant market value, is saying NPs $SLS + Herceptin $RHHBY + Keytruda $MRK is the Best Solution for Her2 Breast Cancer. Results from a randomized trial combining trastuzumab with a peptide vaccine suggest a role for HER2-targeted therapy in triple-negative breast cancer Oncotarget. 2021 Nov 9; 12(23): 2318–2319.
    Finally, treatment with the HER-directed therapy, trastuzumab, has demonstrated upregulation of PD-L1 expression on breast cancer cells in transgenic mouse models, and it is hypothesized that this serves as a possible means of trastuzumab resistance [14]. These immunologic effects of trastuzumab provide the justification for combining immunomodulators such as PD-1/PD-L1 and/or CTLA-4 targeted therapy or HER2-derived peptide vaccines with the HER-directed antibody therapy in an effort to optimize anti-tumor responses.
  • R
    Real Immuno Investor 10
    $SLS conversation
    All 3 have Partnerships with $SLS, interesting. https://www.barrons.com/articles/drug-companies-cash-product-buys-research-51641423117?tesla=y 'Other firms expected to see high swells of cash are Roche Holding ( $RHHBY ), $BMY Bristol Myers, and $MRK Merck.'

    These piles of cash shouldn’t only cheer the shareholders of big pharma firms. Smaller biotech firms will be on the receiving end of licensing or acquisition deals. When Pfizer made its deal for Arena last month, the $100 a share deal was twice Arena’s trading price.
    We searched for the largest drug companies with money to make pipeline-filling buys. Johnson & Johnson, Pfizer, and AbbVie top the list.
    We searched for the largest drug companies with money to make pipeline-filling buys. Johnson & Johnson, Pfizer, and AbbVie top the list.
    www.barrons.com
  • j
    jim
    $XBI conversation
    Curious on the $xBI $IWC $IBB board: If a ( $SLS ) company has annual Revenue of $200M with a Projection up to $600M - and an additional billion beyond that - What is that Worth? dNPv % probabilities. However when the FDA Greenlights GPs for its first AML Indication, that is the kind of Math that becomes Certain.

    8k's re change of control in DEC too, buyout first more likely by one of the existing Partnerships $MRK $BMY $RHHBY
  • B
    Brent
    When MRK advertises on the radio for jobs, you know it's time to buy.
  • R
    Real Immuno Investor 10
    $SLS conversation
    Published online 2021 Nov 9 Dr. Peoples, who conducted the $GLSI trial that added a billion in instant market value, is saying NPs $SLS + Herceptin $RHHBY + Keytruda $MRK is the Best Solution for Her2 Breast Cancer. Results from a randomized trial combining trastuzumab with a peptide vaccine suggest a role for HER2-targeted therapy in triple-negative breast cancer Oncotarget. 2021 Nov 9; 12(23): 2318–2319.
  • C
    Cured
    $SLS conversation
    In addition to the nearly complete REGAL Phase 3 trial, there are two Gps trials in combination Check Point Inhibitors Keytruda & Opdivo, with readouts expected in January: Many billion dollar bios built on lessor P 1/2 Data - Near Miraculous early results from the Mesothelioma trial caused a nice increase in enrollment and Why not, a Gps+Opdivo trial patient at Sloan Kettering is alive 25 months, their life expectancy was only 3. 3 vs 25 - If that patient remains alive at this upcoming readout ---?---- it could be global news.
    Same with the Keytruda Gps patients.
    All patients alive 9 months into that trial for a patient setting where the AVERAGE OS is 9 months.
    15 patient end stage trial and all on GPS Drug remain at the avg duration of the best available therapy - another 6 months of follow up will confirm Gps +K better than all other drugs!
    $mrk
    Second TNBC cohort patient enrollment is now open too, what data they are seeing must be good.
    Induction - look it up I did.
    “Based on these early data, it is encouraging to see the induction of WT1-specific T-cell immune responses with the administration of GPS in combination with pembrolizumab with a validated complex ex-vivo immune response assay on peripheral blood from patients with platinum-refractory metastatic ovarian cancer who had undergone numerous prior therapies,” Jeffrey S. Weber, MD, PhD, the deputy director of the Perlmutter Cancer Center at NYU Langone Health, and chair of SELLAS’ Scientific Advisory Board, added in the press release.

    https://www.cancernetwork.com/view/phase-1-2-trial-shows-positive-data-for-galinpepimut-s-and-pembrolizumab-combination-in-wt1-ovarian-cancer

    https://www.onclive.com/view/galinpepimut-s-plus-pembrolizumab-shows-early-activity-in-advanced-ovarian-cancer

    https://www.onclive.com/view/galinpepimut-s-plus-nivolumab-shows-promising-preliminary-benefit-in-mesothelioma
  • R
    Real Immuno Investor 10
    $SLS conversation
    SLS Science Chair and Lead Investigator of $MRK Pembro for Melanoma
    https://ascopost.com/videos/sitc-2021/jeffrey-weber-on-coronavirus-cancer-and-immunotherapy-navigating-clinical-trials-and-treatment/ . "The steep decline in trial enrollment has recovered, with many of the changes in how research was conducted as a result of the pandemic still in place and improving the process going forward."
  • S
    Stephens
    $SLS conversation
    $GNPX Similar news to upcoming $SLS $MRK $BMY Sls has two trial results to be reported in January
    Shares of Genprex Inc. GNPX, +167.18% skyrocketed 121% on massive volume in afternoon trading Monday, after the gene therapy company said its Reqorsa Immunogene Therapy was granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration for use in combination with Merck & Co. Inc.'s MRK, +0.30% cancer treatment Keytruda. Trading volume exploded to 163.9 million shares, compared with the full-day average of about 476,600 shares, and enough to make the stock the most actively traded on major U.S. exchanges. The company said the FTD is for use in patients with histologically confirmed unresectable stage III or IV non-small cell lung cancer (NSCLC) whose disease progressed after treatment with Keytruda.
  • S
    SushaG
    With MRK’s robust pipeline, cheap stock price and generous dividend it is just a matter of time until Mr Market figures it out and bids the stock price up to higher levels.

    Looking for a rewarding ‘22.
  • P
    Peter
    Why would a Dr. prescribe Merck's Covid drug when the Pfizer drug is much more effective?
  • a
    ageninrussia
    Bertrand Delsuc twtr

    $MRK talking about co-formulations of ICIs with Keytruda like TIGIT, LAG-3, CTLA-4, ILT4, and cytokines in the future. So, co-formulations vs bispecs?